Conversely, the results of a recent retrospective study in mCRPC patients treated with 223RaCl2 indicated that mutations in tumor protein 53 (TP53), breast cancer genes1/2 (BRCA1/2), and phosphatase and tensin homolog (PTEN) are not reliable indicators of treatment response. This evidence concerns the gene TP53 and cancer.